Abstract
Recently, much has been learned about the immunology of multiple sclerosis (MS). However, a mechanistic understanding of currently employed immunomodulatory therapies has lagged behind, hindering both the search for more effective agents and clearer insight into the immunopathogenesis of MS. Christopher Karp and colleagues explore a unifying hypothesis for the mechanism of action of interferon β in MS: suppression of interleukin 12 production.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
